Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Frank KroschinskyJan Moritz MiddekeMartin JanzGeorg LenzMathias Witzens-HarigReda BouabdallahPaul La RoséeAndreas ViardotGilles SallesSeok Jin KimTae Min KimOliver OttmannJoerg ChromikAnne-Marie QuinsonUte von WangenheimUte BurkardAndreas BerkNorbert SchmitzPublished in: Investigational new drugs (2020)
The original version of this article unfortunately contained an error. In the Conflict of interest statement, Anne-Marie Quinson is described as declaring no conflict of interest.
Keyphrases